Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase I Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

NCT03379493 is registered in ClinicalTrials.gov with Eureka Therapeutics Inc. as lead sponsor.

NCT NCT03379493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03379493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase I Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma
Lead sponsor
Eureka Therapeutics Inc.
Phase
Phase 1
Overall status
Terminated
Start date
April 4, 2018
Completion date
January 30, 2019
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphomas non-hodgkin's b-cell